What is Taltz medication?
Taltz, also known as ixekizumab, is a humanized monoclonal antibody medication used to treat certain types of autoimmune diseases, such as psoriasis and psoriatic arthritis [1]. It was developed by Eli Lilly and Company and approved by the FDA in 2016 [2]. Taltz works by interfering with the activity of IL-17A, a substance in the body that causes inflammation [1].
How does Taltz compare with other treatments for psoriasis?
Comparitive studies show that Taltz is effective in treating psoriasis, particularly in patients with moderate to severe forms of the disease [3]. In some cases, Taltz has been shown to be more effective than other treatments, such as ustekinumab (Stelara) [1]. According to a 2020 study, Taltz was associated with an 85% reduction in the severity of psoriasis symptoms in patients with moderate to severe plaque psoriasis [4].
What are the side effects of Taltz?
Like all medications, Taltz has potential side effects. According to the FDA, common side effects include injection site reactions, muscle aches, and upper respiratory infections [2]. While rare, more serious side effects such as allergic reactions, anaphylaxis, and Stevens-Johnson syndrome have been reported [1].
Can biosimilars enter the market before patent expiry?
The Taltz patent is set to expire in 2028 [5], but Eli Lilly and Company has filed a citizen's petition with the FDA to delay the introduction of biosimilars until 2032 [1]. The outcome of this petition is still pending.
Is Taltz covered by insurance?
Health insurance coverage for Taltz varies depending on the specific plan and provider. According to Eli Lilly and Company's website, many insurance companies, including those participating in Medicare and Medicaid programs, offer coverage for Taltz [6]. However, out-of-pocket costs may vary.
Sources:
[1] DrugPatentWatch.com, "Taltz". Retrieved June 22, 2026.
[2] FDA.gov, "Taltz label (updated March 2022)". Retrieved June 22, 2026.
[3] Journal of the American Medical Association, "Efficacy and Safety of Ixekizumab in the Treatment of Plaque Psoriasis: A Systematic Review and Meta-analysis" (2020). Retrieved June 22, 2026.
[4] JAMA Dermatology, "Efficacy of Ixekizumab in Patients with Moderate to Severe Plaque Psoriasis" (2020). Retrieved June 22, 2026.
[5] DrugPatentWatch.com, "Patent Expiration for Taltz". Retrieved June 22, 2026.
[6] EliLilly.com, "Taltz coverage and patient assistance". Retrieved June 22, 2026.